Active targeting involves functionalizing nanoparticles with specific ligands that bind to receptors overexpressed on the surface of target cells. These ligands can be antibodies, peptides, or small molecules that have a high affinity for the target receptors. When administered, these functionalized nanoparticles navigate through the bloodstream and bind to the target cells, facilitating the direct delivery of the therapeutic payload.
